MICRUS MICROCOIL SYSTEM CASHMERE-CERECYTE, MODEL CRC; CASHMERE-SR, MODEL SRC

K072173 · Micrus Endovascular Corporation · HCG · Oct 5, 2007 · Neurology

Device Facts

• Record ID: K072173
• Device Name: MICRUS MICROCOIL SYSTEM CASHMERE-CERECYTE, MODEL CRC; CASHMERE-SR, MODEL SRC
• Applicant: Micrus Endovascular Corporation
• Product Code: HCG · Neurology
• Decision Date: Oct 5, 2007
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 882.5950
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms.

Device Story

Micrus Microcoil Delivery System consists of embolic microcoil attached to single-use, sterile Device Positioning Unit (DPU). Used by neurovascular specialists in clinical settings for endovascular embolization of intracranial aneurysms. Device functions as mechanical implant to occlude aneurysm sac; prevents blood flow into aneurysm, reducing rupture risk. Physician deploys coil via catheter system; output is physical occlusion of aneurysm. No software or algorithmic processing involved.

Clinical Evidence

Bench testing only.

Technological Characteristics

Neurovascular embolic microcoil system. Materials and construction methods identical to predicate devices. Dimensions include wire gauge, pitch, coil stiffness, and length. Sterile, single-use device. No energy source, software, or connectivity.

Indications for Use

Indicated for endovascular embolization of intracranial aneurysms in patients requiring neurovascular intervention.

Regulatory Classification

Identification

A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral ateriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in other vascular applications are also not included in this classification, see § 870.3300.

Special Controls

*Classification.* Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 882.1(e).

Predicate Devices

• Micrus Cashmere-14 Microcoil (K063653)
• Micrus Cerecyte Microcoil (K033813)

Submission Summary (Full Text)

{0}------------------------------------------------

## Summary of Safety and Effectiveness

| Submitter Name and<br>Address: | Micrus Endovascular Corp.<br>821 Fox Lane<br>San Jose, CA 95131 | OCT 5 ° 2007 |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Contact Name: | Patrick Lee<br>Phone: [phone]<br>Fax: [phone]<br>Email: [e-mail] | |
| Preparation Date: | August 3, 2007 | |
| Device Name and<br>Classification: | Micrus Microcoil System<br>Common Name: Micrus “Cashmere-Cerecyte” and “Cashmere-SR”<br>Classification Name: Device, Neurovascular Embolization<br>Regulatory Class II | |
| Predicate Devices: | Micrus Cashmere-14 Microcoil, 510(k) no.K063653<br>Micrus Cerecyte Microcoil, 510(k) no. K033813 | |
| Device Description: | The Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil<br>Systems each consists of an embolic coil (“Microcoil”) attached to<br>Device Positioning Unit (DPU) (single use, sterile) | |
| Device Intended Use | The Micrus Microcoil Delivery System is intended for endovascular<br>embolization of intracranial aneurysms. | |

## Comparison to Predicate Devices:

The Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems have shown substantial equivalence to the Micrus Cashmere-14 Microcoil System and Micrus Cerecyte Microcoil System in terms of intended use, design, material of construction, implant dimensions including wire dimensions, pitch, coil stiffness, and coil length. The Cashmere-Cerecyte and Cashmere-SR microcoils use the same method and material of construction, packaging, and sterilization method as its predicates. The modification has not altered the fundamental technology of the sponsor's predicate device

## Conclusion:

Based upon the design, materials, function, intended use, comparison with currently marketed devices and the non-clinical testing performed by Micrus Endovascular Corporation, it is concluded that the Micrus Cashmere-Cerecyte and Cashmere-SR Microcoil Systems are substantially equivalent to the predicate devices in safety and effectiveness.

{1}------------------------------------------------

Image /page/1/Picture/12 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized eagle with its wings spread, symbolizing protection and service. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The seal is simple and monochromatic.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Micrus Endovascular Corporation % Mr. Patrick Lee Regulatory Affairs Specialist 821 Fox Lane San Jose, California 95131

OCT 5 2007

Re: K072173

Trade/Device Name: Micrus Microcoil Delivery System Regulation Number: 21 CFR 882.5950 Regulation Name: Neurovascular embolization device Regulatory Class: II Product Code: HCG Dated: September 06, 2007 Received: September 07, 2007

Dear Mr. Lee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{2}------------------------------------------------

Page 2 - Mr. Patrick Lee

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely vours.

Barbara Buchner
dos

Mark N. Melk Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Page 3 - Mr. Patrick Lee

cc: HFZ-401 DMC HFZ-404 510(k) Staff HFZ-410 Division D.O. f/t:TRN:kxl:10-04-07

.OC Numbers:

| Division of Enforcement A | 240-276-0115 |
|-----------------------------------------------------------|--------------|
| Dental, ENT and Ophthalmic Devices Branch | 240-276-0115 |
| OB/GYN, Gastro. & Urology Devices Branch | 240-276-0115 |
| General Hospital Devices Branch | 240-276-0115 |
| General Surgery Devices Branch | 240-276-0115 |
| Division of Enforcement B | 240-276-0120 |
| Cardiovascular & Neurological Devices Branch | 240-276-0120 |
| Orthopedic, Physical Medicine & Anesthesiology Devices Br | 240-276-0120 |

:

:

.

{4}------------------------------------------------

## Indications for Use

510(k) Number (if known): _

Micrus Microcoil Delivery System Device Name: _

Indications For Use:

The Micrus Microcoil Delivery System is intended for endovascular embolization of intracranial aneurysms.

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Barbara Mann
(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

**510(k) Number** K072173
Page 1 of 1